Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 8c

Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q2 EPS of ($0.75), $0.08 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.

You May Also Be Interested In

• Lyntris opens at $15.50, below IPO price of $17.50
• North Korea dismisses US military drill cuts, denies Trump talks
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates